Revised mammography policy
This article was originally published in The Gray Sheet
Executive Summary
Facilities will need to respond to FDA within 15 days for a Level I, repeat Level I or repeat Level II observation, instead of waiting to receive a warning letter from the agency and responding within 30 days, effective Oct. 1. FDA may choose to re-inspect the facility if its written response is not sufficient or if the facility fails to respond...